Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a ...
・Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program. ...
Federal data indicate that over half the US population aged 6-46 years is infected with cytomegalovirus (CMV), typically spread through bodily fluids. Most people have mild or no negative effects from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results